Nyasha Veronica Dzavakwa

Nyasha Veronica Dzavakwa

Auto-generated profile, based on publicly available information

Nyasha Veronica Dzavakwa

Biomedical Research and Training Institute, Avondale, Harare, Zimbabwe

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Trials
Verified
Journal Article
Open access
PDF file
NDNyasha Veronica Dzavakwa
Nyasha Veronica Dzavakwa
MCMolly Chisenga
Molly Chisenga
GMGrace McHugh
Grace McHugh
SFSuzanne Filteau
Suzanne Filteau
CGCelia Louise Gregson
Celia Louise Gregson
TTthe VITALITY team
the VITALITY team
Background: Of the 2 million children living with HIV globally, 90% live in sub-Saharan Africa. Despite antiretroviral therapy, longstanding HIV infection is associated with several chronic complications in children including growth failure, particularly stunting and delayed puberty. Vitamin D deficiency, which is highly prevalent among children living with HIV in sub-Saharan Africa, has a further adverse impact on bone health. This trial aims to establish whether supplementation with vitamin D3 and calcium carbonate improves musculoskeletal health among peripubertal children living with HIV. Methods/design: We will conduct an individually randomised, double-blinded, placebo-controlled trial of weekly high-dose vitamin D3 (20,000 IU) plus daily calcium carbonate (500mg) supplementation for 48 weeks. Eight hundred and forty children living with HIV aged 11–19 years taking ART for ≥6 months will be enrolled and followed up for 96 weeks. The primary outcome is total body less-head bone mineral content for lean mass adjusted for height (TBLH-BMCLBM) Z-score at 48 weeks, measured by dual-energy X-ray absorptiometry (DEXA). Secondary outcomes are DEXA-measured lumbar spine bone mineral apparent density Z-score, number of respiratory infections, lean muscle mass and grip strength at 48 and 96 weeks and TBLH-BMCLBMZ-scores at 96 weeks. Sub-studies will investigate the effect of the intervention on vitamin D3 pathway metabolites and markers of bone turnover, intestinal microbiota, and innate and acquired immune function. Discussion: This is the largest trial to date of vitamin D supplementation in children living with HIV. Intervening to address deficits in bone accrual in childhood is critical for optimising adolescent and early adult bone health and prevention of later adult osteoporotic fractures. Trial results will draw attention to the need to screen for and treat long-term comorbidities in children living with HIV in resource-limited settings. Trial registration: Pan African Clinical Trials Registry PACTR20200989766029. Registered on 3 September 2020

22 July 2024 in Trials
Verified
Journal Article
Open access
PDF file
NDNyasha Veronica Dzavakwa
Nyasha Veronica Dzavakwa
MCMolly Chisenga
Molly Chisenga
GMGrace McHugh
Grace McHugh
SFSuzanne Filteau
Suzanne Filteau
CGCelia Louise Gregson
Celia Louise Gregson
HWHelen A. Weiss
Helen A. Weiss
Background: Of the 2 million children living with HIV globally, 90% live in sub-Saharan Africa. Despite antiretroviral therapy, longstanding HIV infection is associated with several chronic complications in children including growth failure, particularly stunting and delayed puberty. Vitamin D deficiency, which is highly prevalent among children living with HIV in sub-Saharan Africa, has further adverse impact on bone health. This trial aims to establish whether supplementation with vitamin D3 and calcium carbonate improves musculoskeletal health among peripubertal children living with HIV. This paper is an update to an already existing protocol that was previously published in Trials in 2022 and details changes in the trial outcomes. Methods/design: We will conduct an individually randomised, double-blinded, placebo-controlled trial of weekly high-dose vitamin D3 (20,000 IU) plus daily calcium carbonate (500 mg) supplementation for 48 weeks. Eight hundred and forty children living with HIV aged 11–19 years taking ART for ≥ 6 months will be enrolled and followed up for 96 weeks. The primary outcome is DXA-measured total body less-head bone mineral density Z-score (TBLH-BMD) at 48 weeks and is an update to the previous primary outcome total body less-head bone mineral content adjusted for lean mass (TBLH-BMCLBM) Z-score. The primary outcome was updated to address the substantial differences in distributions of TBLH-BMCLBM Z-score between the two sites as a result of software differences of the DXA machines. Secondary outcomes are DXA-measured TBLH-BMD Z-score adjusted for height at 48 weeks a new secondary outcome, lumbar spine bone mineral apparent density Z-score, number of respiratory infections, lean muscle mass and grip-strength at 48 and 96 weeks, and TBLH-BMD Z-score at 96 weeks. Sub-studies will investigate the effect of the intervention on vitamin D3 pathway metabolites and markers of bone turnover, intestinal microbiota, and innate and acquired immune function. Discussion: This is the largest trial to date of vitamin D supplementation in children living with HIV. Intervening to address deficits in bone accrual through childhood is critical for optimising adolescent and early adult bone health, and prevention of later adult osteoporotic fractures. Trial results will draw attention to the need to screen for and treat long-term comorbidities in children living with HIV in resource-limited settings. Trial registration: Pan African Clinical Trials Registry PACTR20200989766029. Registered on September 3, 2020. URL of trial registry record: https://pactr.samrc.ac.za Trial status: Participant follow-up completed; data analysis ongoing.

7 September 2024 in International Journal of Nursing Studies
Verified
Journal Article
Open access
NDNyasha V. Dzavakwa
Nyasha V. Dzavakwa
KKKatharina Kranzer
Katharina Kranzer
PKPalwasha Khan
Palwasha Khan
CMConstance R.S. Mackworth-Young
Constance R.S. Mackworth-Young
HMHilda A. Mujuru
Hilda A. Mujuru
VSVictoria Simms
Victoria Simms
Objective: To systematically review literature from randomised controlled trials (RCTs) investigating the effectiveness of electronic monitoring device informed interventions on adherence and clinical outcomes in children and adolescents with chronic conditions. Study design: A systematic review was conducted. An electronic literature search covering studies, with no pre-specified starting date up to June 2024, was performed in Medline, EMBASE, Web of Science, Cochrane and Trials databases was conducted. Participants: RCTs of electronic monitoring device informed interventions in individuals aged 0 to 18 years with chronic conditions, were identified, with no restriction on geography or publication date. Methods: Extracted data was synthesised. As a result of differences in definitions and analysis of adherence and clinical outcomes across the studies a pooled meta-analysis was not possible therefore, a descriptive analysis was conducted. Risk of bias across all studies was assessed using the Cochrane Collaboration risk of bias tool. Results: 11 RCTs, with 1485 children and adolescents were included. Studies were all from high- and middle-income countries, conducted among children and adolescents with asthma, and one each among children and adolescents with kidney transplant, multiple sclerosis, and epilepsy. Eight of the 11 studies reported a positive effect on adherence. Only four studies reported a positive effect on clinical outcomes and seven studies found no effect on clinical outcomes. Conclusions: Electronic monitoring device interventions show promise in improving adherence in children and adolescents with chronic conditions, in a limited number of chronic conditions, mostly asthma. Evidence for the efficacy of electronic monitoring device informed interventions on clinical outcomes and from low-income settings is lacking. Systematic review registration PROSPERO, CRD42022312057, registered in March 2022. Tweetable abstract Electronic monitoring device informed interventions may improve treatment adherence in children and adolescents with chronic conditions but evidence from low-income settings is lacking @nyasha_dzavakwa @KatharinaKranz4 @dopapus @hilda_mujuru @rashida_abbferr @vickysimms_epi

30 August 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NDNyasha V Dzavakwa
Nyasha V Dzavakwa
VSVictoria Simms
Victoria Simms
CGCelia L Gregson
Celia L Gregson
MCMolly Chisenga
Molly Chisenga
SFSuzanne Filteau
Suzanne Filteau
MTMizinga Tembo
Mizinga Tembo
Stunting and pubertal delay are common among children growing up with human immunodeficiency virus (HIV) and are associated with bone and muscle impairments. We investigated factors associated with bone density and muscle function in adolescents living with HIV (ALWH). The VITALITY trial (PACTR202009897660297) investigated whether vitamin D and calcium supplementation improves musculoskeletal health among ALWH. A total of 842 ALWH aged 11–19 years, established on antiretroviral therapy (ART) for ≥6 months, were enrolled from HIV clinics in Zambia and Zimbabwe. Clinical history and examination were undertaken, and serum 25-hydroxyvitamin D3 (25[OH]D3) was measured. Dual-energy X-ray absorptiometry measured total-body-less-head bone mineral density adjusted for height (TBLH-BMDHT), and lumbar spine bone mineral apparent density (LS-BMAD) z scores. The association between a priori–defined covariates and musculoskeletal outcomes were investigated using baseline enrollment data and multivariable logistic regression. TBLH-BMDHT z scores were impaired (mean, −1.42 for male and −0.63 female participants), as were LS-BMAD z scores (mean −1.15 for male and −0.47 for female participants). In bivariate analysis, early pubertal stage, less physical activity, and older age at ART initiation were associated with lower TBLH-BMDHT z scores. Younger age, early pubertal stage, and low socioeconomic status were associated with lower LS-BMAD z scores. Grip-strength-for-height and jump-power-for-height z scores were associated with lower TBLH-BMDHT and LS-BMAD z scores. Low dietary vitamin D and calcium were associated with lower adjusted TBLH-BMDHT z scores. Lower 25(OH)D3 was associated with lower adjusted TBLH-BMDHT and LS-BMAD z scores. Deficits in bone density are common in ALWH. Vitamin D and calcium supplementation and promotion of exercise may improve musculoskeletal health among perinatally infected ALWH.

7 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
JSJulian P G Shellard
Julian P G Shellard
ECEmily Carr
Emily Carr
GTGianni Tam-McMillan
Gianni Tam-McMillan
EMEmma W Mao
Emma W Mao
HMHilda Angela Mujuru
Hilda Angela Mujuru
AHAnthony Y Y Hsieh
Anthony Y Y Hsieh
Background: Human immunodeficiency virus (HIV-1) infection leads to reduced telomere length (TL), a biomarker of immune aging. We investigated relationships between HIV viral load (VL) and CD4 count with TL and its rate of attrition in children with HIV from Zambia and Zimbabwe. Methods: Buffy coat was obtained at baseline and 48 weeks from children aged 11–19 years with perinatally acquired HIV taking combination antiretroviral therapy (cART) for >6 months recruited into the VITALITY trial. Relative TL was measured using monochrome multiplex quantitative polymerase chain reaction, standardizing units for analysis. Cross-sectional analyses used multivariable linear regression adjusting for age, sex, and study site; longitudinal analysis additionally adjusted for baseline TL. Results: Among participants at baseline (N = 842; mean ± SD age, 15.5 ± 2.6 years; 53.2% female), 678 (80.5%) had HIV VL 1000 copies/mL. The mean CD4 count was 584 ± 243 cells/μL. Compared to participants with VL 1000 copies/mL had shorter TL (β = −.239 [95% confidence interval {CI}, −.451 to −.026]; P = .028), whereas those with 60–1000 copies/mL did not (P = .836). Lower CD4 cell count was associated with shorter TL (β = −.038 [95% CI, −.009 to −.066] per 100 CD4 cells/μL; P = .009). In longitudinal analysis (n = 783) after mean 336 ± 6 days, those with HIV VL >1000 copies/mL at both timepoints had an accelerated telomere attrition rate (β = −.276 [95% CI, −.546 to −.005]; P = .046) compared with participants with VL 1000 copies/mL among children with HIV on cART in Africa is associated with a degradation of immune age within 1 year, which may increase risk of comorbidities later in life. Clinical Trials Registration: PACTR202009897660297.

6 May 2025 in Medicine: Case Reports and Study Protocols
Verified
Journal Article
Open access
NDNyasha V. Dzavakwa
Nyasha V. Dzavakwa
MPMazvita Bsc Paradza
Mazvita Bsc Paradza
DKDebra Bsc Kembo
Debra Bsc Kembo
MCModester Msc Chidembo
Modester Msc Chidembo
DMDebson Bsc Munemo
Debson Bsc Munemo
VSVictoria Simms
Victoria Simms
Background: Adherence to antiretroviral therapy (ART) among young people living with human immunodeficiency virus (YPLWH) is lower than in other age-groups. Electronic monitoring devices may improve adherence behavior in chronic diseases. We hypothesized that use of electronic monitoring devices paired with text message reminders and adherence feedback may improve viral suppression among YPLWH. Methods/design: An individual randomized, controlled trial will be conducted from September 2023 to January 2025 in Harare, Zimbabwe. YPLWH aged 16 to 30 years, with a viral load (VL) > 200 copies/mL will be enrolled from human immunodeficiency virus outpatient clinics. Participants will be randomized to intervention or standard of care (existing enhanced adherence counseling services) and followed up for 9 months. Participants randomized to the intervention arm will be asked to keep and take their ART tablets daily from an EMD that is configured to send text message reminders to their mobile telephone if no pill box opening event has been recorded 30-minutes after scheduled intake time. Monthly focused individual and in-person adherence feedback sessions will be conducted to discuss EMD-recorded adherence. The primary outcome is proportion of participants with viral suppression (VL < 50 copies/mL) at 6 months. Secondary outcomes are proportion of participants with VL < 50 copies/mL at 9 months, mean adherence to ART at 6 and 9 months, change of ART regimen, and exploration of adherence patterns using machine learning. A mixed methods process evaluation will be conducted concurrently with the trial to explore feasibility, fidelity, and acceptability of the intervention in participants randomized to the intervention arm. Conclusion: Findings of this trial will provide evidence for the effectiveness and feasibility of digital adherence interventions for young people taking long-term therapies.